One doesn’t have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R&D productivity. However, these factors are driving smaller organizations and individuals to take on small molecule and biological drug development, sometimes with great success.